The Russian Ministry of Health has approved the inclusion of a warning about a new side effect in the instructions for the medical use of drugs containing erenumab. The information is published on the GRLS website.
When analyzing the regulatory authorities of the ICH member countries, it was found that in September, the Australian Therapeutic Goods Administration reported the risk of developing arterial hypertension due to the use of medications with this component.
Erenumab (trade name Irinex) is registered the State Register of Medicines (GRLS) (reg. number LP-006083 dated 19.01.2021).
Erenumab is a human monoclonal antibody, calcitonin gene-related peptide (CGRP) receptor antagonist associated with the pathophysiology of migraine.